Will Metabolic Syndrome Emerge as a Commercial Market?

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction
• An Overview of Metabolic Syndrome
  • Disease Defi nition
  • Prevalence
• Is Metabolic Syndrome a Discrete Disease?
  • Perspective of Regulatory Agencies
  • Perspective of Payers
• Current Treatment Options
  • FDCs to Treat Dyslipidemia/Hypertension (Pfi zer' s Caduet)
  • Agents to Treat Obesity
  • Agents to Treat Diabetes
• Strategies for Developing Agents for Metabolic Syndrome
  • Multimodal Approaches
    • Peroxisome Proliferator-Activated Receptor Agonists
    • Cortisol Modulators
  • Fixed-Dose Combinations
• What Is the Future for Metabolic Syndrome Treatment?

Tables

• 1. Defi nitions for Metabolic Syndrome
• 2. Prevalent Cases of Metabolic Syndrome, 2006
• 3. Metabolic Syndrome: Current Therapies and 2006 Worldwide Sales
• 4. Agents in Development to Treat Multiple Components of Metabolic Syndrome
• 5. Agents in Development to Treat Single Components of Metabolic Syndrome

Figures

• 1. Prevalent Cases of Metabolic Syndrome and Component Diseases in the Seven Major Markets, 2006
• 2. Prescriptions Attributed to Metabolic Syndrome in the United States, 2000-2006
• 3. Disease Targets of Multimodal and Fixed-Dose Combination Agents for Metabolic Syndrome Components